Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.

@article{Krakowsky2019RiskOT,
  title={Risk of Testosterone Flare in the Era of the Saturation Model: One More Historical Myth.},
  author={Yonah Krakowsky and Abraham Morgentaler},
  journal={European urology focus},
  year={2019},
  volume={5 1},
  pages={
          81-89
        }
}
View on PubMed
doi.org
16 Citations
Highly Influential Citations
2
Background Citations
6

16 Citations

Safety of testosterone therapy in men with prostate cancer

Although more safety studies are needed, TTh is a reasonable therapeutic option for men with low-risk PCa after surgery or radiation, and data in men on active surveillance are limited, but initial reports are reassuring.

Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.

In this phase 3 trial involving men with advanced prostate cancer, relugolix achieved rapid, sustained suppression of testosterone levels that was superior to that with leuprolide, with a 54% lower risk of major adverse cardiovascular events.

Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer

It is presented a hypothesis, and preliminary evidence based on previous randomized controlled trials, that androgen surge during radiation, rather than its suppression, could be responsible for the enhanced prostate cancer cell kill during radiation.

HERO trial: A rescue from injectable androgen deprivation therapy

  • S. Ranjan
  • Medicine, Biology
    Indian journal of urology : IJU : journal of the Urological Society of India
  • 2021
The HERO trial enrolled PCa patients who either relapsed after curative local treatment or had incurable locally advanced disease or newly diagnosed with hormone-sensitive metastatic disease, and the primary end point was sustained castrate level of testosterone.

Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.

Results from the analysis indicate that testosterone breakthroughs likely result in worse clinical outcomes and should be avoided, and there is a need to standardize assessment of testosterone levels both clinically and in the research context.

RRU_A_303215 87..108

A general overview of the evolution of ADT in the context of the new emerging pharmaceutical ADT modalities is provided so that clinicians and medical providers have a better understanding of personalizing the available ADT options with their different risk-benefit profiles.

Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers

A general overview of the evolution of ADT in the context of the new emerging pharmaceutical ADT modalities is provided so that clinicians and medical providers have a better understanding of personalizing the available ADT options with their different risk-benefit profiles.

Therapeutic effects of the combined androgen blockade therapy versus luteinizing hormone-releasing hormone analog monotherapy in patients with hormone naïve metastatic prostate cancer: a multi-institutional comparative analysis

No significant differences in oncological outcomes were observed between the CAB and LH-RHa monotherapy groups in patients with mHNPC and IPTW-adjusted multivariate Cox hazard proportional analyses showed no significant differences between the two groups.

Testosterone Therapy in a Man with Intermediate-risk Prostate Cancer: Pro.

Metabolic Alterations, Aggressive Hormone-Naïve Prostate Cancer and Cardiovascular Disease: A Complex Relationship

A careful evaluation of obesity, diabetes mellitus, dyslipidemia, systemic arterial hypertension, together with a careful Evaluation of cardiovascular status, in particular coronary and carotid vascular disease, should be carried out after an initial diagnosis of prostatic carcinoma.

References

SHOWING 1-10 OF 47 REFERENCES

Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?

A new era of testosterone and prostate cancer: from physiology to clinical implications.

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.

Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade.

Testosterone and prostate cancer: an historical perspective on a modern myth.

The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis

This meta-analysis shows that regardless of the administration method, TRT is the short-term safety and does not promote prostate cancer development or progression but long-term data are warranted with justifiable end points.

Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.

Combination treatment in M1 prostate cancer

It is emphasized that total androgenic blockage is as effective as a luteinizing hormone‐releasing hormone analog used alone as opposed to the complete androgen blockage used alone.

Optimal Starting Time for Flutamide to Prevent Disease Flare in Prostate Cancer Patients Treated with a Gonadotropin-Releasing Hormone Agonist

Simultaneous administration of flutamide with a GnRH agonist is sufficient to prevent flare-up phenomena in patients with prostate cancer and elevated serum levels of PSA.

Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare?